Pharmacokinetic interactions between statins and fibrates.
Concomitant use of a fibrate and a statin may offer a therapeutic advantage to patients with dyslipidemia, especially in patients whose low-density lipoprotein cholesterol is controlled by statins but whose high-density lipoprotein cholesterol or triglycerides, or both, are not within goal. However, concern about drug-drug interactions may preclude optimal use of combination statin-fibrate therapy. This article reviews the pharmacokinetics between statins and fibrates, addressing risks associated with drug-drug interactions and combination therapy.
Corsini
Alberto
A
Department of Pharmacological Sciences, University of Milan, Milan, Italy. Alberto.corsini@unimi.it
Bellosta
Stefano
S
Davidson
Michael H
MH
D019540:Area Under Curve; D001682:Biological Availability; D002995:Clofibric Acid / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004338:Drug Combinations; D004347:Drug Interactions; D050171:Dyslipidemias / Q000188:drug therapy* / Q000378:metabolism; D006207:Half-Life; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D007408:Intestinal Absorption; D012206:Rhabdomyolysis / Q000139:chemically induced; D012307:Risk Factors
D004338:Drug Combinations; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002995:Clofibric Acid